Vnitr Lek 2021, 67(7):412-418 | DOI: 10.36290/vnl.2021.109

Cardiovascular prevention: early and consistent prevention versus late intervention, complex approach to the treatment of modifiable risk factors: hypertension and dyslipidemia

Lukáš Zlatohlávek
3. interní klinika 1. LF UK a VFN, Praha

Cardiovascular diseases (not including COVID-19 infection) are still one of the most common causes of mortality and morbidity in our country and in developed countries. Today no one questions the intervention of all risk factors for atherosclerosis after a cardiovascular event, although unfortunately even in this case the recommended target values are often not achieved. However, the intervention of risk factors in primary prevention is often neglected. Atherosclerosis is a long-term process, developing since the childhood. It is a continuous process and the event itself is only the culmination of this process. Therefore, it is necessary to intervene in key risk factors early in life, and we have ample evidence that even early pharmacological intervention has a clear effect on slowing or stopping the process of atherosclerosis.

Keywords: risk factors of atherosclerosis, dyslipidemia, arterial hypertension, early intervention.

Published: November 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zlatohlávek L. Cardiovascular prevention: early and consistent prevention versus late intervention, complex approach to the treatment of modifiable risk factors: hypertension and dyslipidemia. Vnitr Lek. 2021;67(7):412-418. doi: 10.36290/vnl.2021.109.
Download citation

References

  1. www.czso.cz
  2. Zhang Y et al. Associations of Blood Pressre and Choelsterol levels During Young Adulthood With Later Cardiovaskular Events, J Am cool Cardiol 2019 July 23; 74(3): 330-341. Go to original source... Go to PubMed...
  3. Ference et al. Association of Genetic Variants Related to Combined Exposure to Lower Low‑Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease, JAMA, 2/2019, E 1-11.
  4. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, European Heart Journal (2019) 00, 1-78.
  5. SCORE2 working group and ESC Cardiovascular risk collaboration: SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2439-2454.
  6. SCORE2-OP working group and ESC Cardiovascular risk collaboration: SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2455-2467.
  7. Sabatine MS, Giugliano RP, Keech AC, for the FO RIER Steering Committee and Investigators: Evolocumab and Clincal Ou comes in Patients with Cardiovascular Disease, N Engl J Med 2017; 376:1713-1722. Go to original source... Go to PubMed...
  8. Feron O, Dessy C, Desager JP et al. Hydroxy‑methylglutaryl‑coenzyme A inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveoline abundance. Circulation 2001; 103: 113-118. Go to original source... Go to PubMed...
  9. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582-587. Go to original source... Go to PubMed...
  10. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‑than‑average cholesterol concentrations, in the Anglo‑Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT‑LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5; 361(9364): 1149-1158. Go to original source... Go to PubMed...
  11. Gupta A, Mackay J, Whitehouse A et al. ASCOT Legacy study. Lancet 2018; 392: 1127-1137. Go to original source... Go to PubMed...
  12. Widimský J jr, Filipovský J, Ceral F et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017, Hypertenze a kardiovaskulární prevence, Supplementum, 2017.
  13. Zlatohlávek L et al. Klinická dietologie a výživa, CurrentMedia, Praha, 2016.
  14. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40: 326-345. Go to original source... Go to PubMed...
  15. Fox KM. The EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double‑blind, placebo‑controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source... Go to PubMed...
  16. Bruining N, deWinter S, Roaelandt JR et al. The Perspective study, Coron Artery Dis 2009, 20: 409-414. Go to original source... Go to PubMed...
  17. Špinar J, Vítovec J. Studie ADVANCE. Remedia 2008; 18: 168-170. Go to original source...
  18. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin‑converting enzyme inhibitors reduce mortality in hypertension: a meta‑analysis of randomized clinical trials of renin‑angiotensin‑aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33: 2088-2097. Go to original source... Go to PubMed...
  19. Bruno et al. Early and Supernormal VAscular Aging, Hypertension, 2020; 76: 1-9. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.